Umeclidinium Bromide
Sold as Incruse Ellipta. Every branded application for this active ingredient.
- First approved: Apr 30, 2014
- Branded applications: 1
- New uses approved: 2
- Complete response letters: 0
Applications
NDAs and BLAs for this ingredient, oldest first; each opens its full history| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 30, 2014 | Incruse ElliptaNDA 205382 · New formulation or manufacturer | Glaxo Grp England | 5 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA